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Background:	   Incidental	   meningiomas	   are	   increasingly	   being	   diagnosed	   due	   to	  widespread	  use	  of	  brain	  imaging.	  	  Treatment	  options	  include	  surveillance,	  surgery	  and	  stereotactic	   radiosurgery,	   but	   the	   natural	   history	   of	   these	   tumours	   is	   not	   fully	  understood	  and	  there	  are	  no	  accepted	  management	  guidelines	  to	  aid	  clinical	  decision-­‐making.	  	  The	  aim	  of	  this	  study	  was	  to	  assess	  current	  practice	  in	  the	  United	  Kingdom	  and	  identify	  areas	  of	  variation	  for	  further	  study.	  	  Methods:	  A	  questionnaire	  was	  distributed	  to	  all	  members	  of	  the	  Society	  of	  British	  Neurosurgeons	  (SBNS).	  	  The	  main	  components	  of	  the	  survey	  included	  the	  assessment	  of	  which	  factors	  and	  tumour	  characteristics	  are	  considered	   in	   the	   management	   and	   follow-­‐up	   of	   incidental	   meningiomas.	   	   Two	   case	  scenarios	  were	  also	  presented.	   	  Results:	  The	  response	  rate	  was	  12.5%	  (44	  completed	  surveys)	   with	   74%	   (25/34)	   of	   neurosurgical	   centres	   represented.	   	   Absence	   of	  calcification	   was	   only	   considered	   by	   36%	   (16/44)	   of	   neurosurgeons.	   	   Most	  neurosurgeons	  opt	   for	   surveillance	  at	   initial	  presentation,	  and	   the	   length	  of	   follow-­‐up	  was	  5	  years	  (14/33)	  and	  10	  years	  (11/33).	  	  The	  case	  scenarios	  highlighted	  that	  tumour	  growth	  at	   follow-­‐up	  resulted	  in	  a	  preference	  to	  change	  from	  surveillance	  to	  treatment	  with	   surgery	   or	   SRS.	   	   SRS	   was	   preferred	   in	   skull-­‐base	   (23/36)	   and	  medial	   sphenoid	  wing	   (16/39)	   tumours.	   	   Conclusions:	   This	   survey	   has	   demonstrated	   that	   certain	  aspects	   of	   incidental	   meningioma	   management	   show	   variation	   and	   remain	  controversial.	   	   Further	   research	   through	   prospective	   cohort	   studies	   is	   required	   to	  provide	  evidence	  to	  support	  guidelines	  for	  the	  management	  of	  incidental	  meningiomas.	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Meningiomas	  are	  the	  commonest	  primary	  brain	  tumour	  and	  the	  incidence	  varies	  from	  1	  -­‐	   8.4	   per	   100,000	   and	   rises	   progressively	   with	   each	   decade	   of	   life	   1.	   	   Symptomatic	  meningiomas	   cause	   headache,	   epilepsy	   or	   focal	   neurological	   deficit	   and	   have	   clearly	  defined	   management	   algorithms	   that	   involve	   surgery	   as	   the	   first	   line	   treatment.	  	  Meningiomas	  may	   also	   be	   diagnosed	   as	   incidental	   findings	   on	   computed	   tomography	  (CT)	  or	  magnetic	  resonance	  imaging	  (MRI)	  performed	  for	  other	  reasons,	  such	  as	  minor	  head	   injury.	   	   The	   widespread	   availability	   of	   MRI	   has	   led	   to	   increased	   reporting	   of	  incidental	   findings,	   and	   patients	   are	   becoming	   so-­‐called	   Victims	   Of	   Modern	   Imaging	  Technology	  (VOMIT)	  2.	  	  The	  finding	  of	  an	  incidental	  meningioma	  leads	  to	  patient	  anxiety	  and	  uncertainty	   about	   the	   future	   3.	  The	  majority	  of	   Incidental	  meningiomas	  are	   small	  but	  they	  all	  have	  growth	  potential	  and	  may	  become	  symptomatic	  4.	  	  Whilst	  these	  can	  be	  treated	  with	  surgery	  or	  stereotactic	  radiosurgery	  (SRS),	  this	  may	  be	  an	  unnecessary	  risk	  for	  the	  patient	  if	  the	  meningioma	  does	  not	  grow	  and	  remains	  asymptomatic.	  	  The	  aim	  of	  this	  study	  was	  to	  survey	  the	  current	  clinical	  practice	  of	  UK	  neurosurgeons	  with	  regards	  to	  the	  management	  of	  incidental	  meningiomas.	  
Materials	  and	  Methods	  
Clinical	  practice	  questionnaires	  were	  emailed	   to	   all	  members	  of	   the	  Society	  of	  British	  Neurological	  Surgeons	  (SBNS).	  	  The	  questionnaire	  was	  approved	  by	  the	  SBNS	  academic	  committee.	  	  There	  are	  approximately	  349	  consultant	  neurosurgeons	  in	  the	  UK	  and	  those	  with	  a	  predominantly	  adult	  and	  cranial	  clinical	  practice	  were	   invited	  to	  respond.	   	  The	  survey	  was	  open	  between	  13th	  April	  2015	  and	  19th	  June	  2015	  -­‐	  a	  second	  email	  reminder	  was	  issued	  after	  one	  month	  and	  a	  £50	  gift	  voucher	  prize	  draw	  was	  used	  as	  an	  incentive.	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  The	   survey	   was	   designed	   to	   collect	   data	   on:	   (i)	   departmental	   protocols,	   (ii)	   patient	  factors	   including	  age	  and	  co-­‐morbidities,	   (iii)	  MRI	   factors	  such	  as	   tumour	   location,	  T2	  signal	   change	   and	   calcification,	   (iv)	  MRI	   follow-­‐up	   schedules,	   and	   (v)	  management	   of	  two	  case	  scenarios	  (Figure	  1A-­‐B	  &	  Table	  1)	  
Results	  
A	   total	   of	   44	   responses	  were	   received	   from	   349	   consultant	   neurosurgeons	   contacted	  across	   the	   UK	   (12.6%	   response	   rate).	   	   There	   was	   a	   good	   geographical	   distribution	  covering	  25	  neurosurgical	  units.	  	  The	  number	  of	  incidental	  meningiomas	  reported	  in	  UK	  neurosurgical	   centres	   ranged	   from	  15-­‐	  150	  a	   year.	   	  Only	   two	  units	   reported	  having	   a	  departmental	  protocol	  for	  the	  management	  of	  these	  tumours.	  
Decision	  making	  factors	  considered	  at	  initial	  clinical	  encounter	  
The	   question	   regarding	   this	   subject	  was	   completed	   by	   all	   44	   neurosurgeons.	   	   Patient	  preference	  was	  considered	  by	  96%	  (42/44)	  of	  responders.	  Patient	  age	  was	  taken	   into	  account	  by	  89%	  (39/44).	  	  Co-­‐morbidities	  influenced	  clinical	  judgement	  in	  89%	  (39/44)	  of	  responders.	  	  Tumour	  location	  and	  tumour	  size	  were	  considered	  by	  96%	  (42/44)	  and	  93%	  (41/44)	  respectively.	  	  Absence	  of	  calcification	  was	  regarded	  as	  an	  important	  factor	  by	   36%	   (16/44)	   and	   peri-­‐tumoural	   T2	   signal	   change	   by	   77%	   (34/44)	   (illustrated	   in	  Figure	   2A).	   	   Other	   factors	   highlighted	   by	   some	   neurosurgeons	   as	   free	   text	   responses	  included	  patient	  occupation,	  importance	  of	  driving,	  radiological	  uncertainty,	  presence	  of	  mass	  effect	  and	  past	  medical	  history	  of	  malignancy.	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Follow-­‐up	  MRI	  schedules	  
Responses	   concerning	   MRI	   timing	   were	   completed	   by	   all	   44	   neurosurgeons.	   	   The	  majority	  neurosurgeons	  opt	  for	  an	  initial	  first	  follow-­‐up	  MRI	  at	  6	  months	  (34/44;	  77%),	  and	  then	  move	  patients	  onto	  a	  subsequent	  12	  monthly	  MRI	  (40/44;	  91%)	  as	  shown	  in	  Figure	  2B.	  	  In	  free	  text	  responses	  some	  neurosurgeons	  commented	  that	  the	  initial	  follow	  up	  MRI	  timing	  also	  depends	  on	  meningioma	  size	  and	  previous	  cancer	  history.	  	  Only	  33	  neurosurgeons	  completed	  the	  section	  on	  long-­‐term	  follow	  up.	   	  Discharge	  from	  regular	  clinical	  follow-­‐up	  was	  considered	  by	  95%	  (42/44).	  	  Patients	  who	  had	  a	  stable	  MRI	  scan	  were	  discharged	  at	  5	  years	  by	  42%	  (14/33)	  and	  at	  10	  years	  by	  33%	  (11/33).	  	  Follow-­‐up	  for	   over	   10	   years	   was	   preferred	   by	   24%	   (8/33).	   	   Other	   reasons	   offered	   as	   free	   text	  responses	   for	   discharge	   from	   follow	   up	   included	   advanced	   age	  with	   heavily	   calcified	  tumour,	  slow	  growing	  tumour	  or	  significant	  co-­‐morbidities	  (Figure	  2B).	  	  
Case	  Scenarios	  
For	  both	  case	  scenarios	  at	  initial	  presentation,	  the	  majority	  of	  neurosurgeons	  opted	  for	  a	  conservative	  approach.	   	  Observation	  with	  MRI	  surveillance	  at	   first	  presentation	  was	  preferred	  by	  89%	  (39/44)	  for	  case	  1	  and	  96%	  (42/44)	  for	  case	  2.	  	  At	  follow-­‐up	  for	  case	  1,	   most	   opted	   for	   surgical	   resection	   (21/44;	   48%)	   and	   only	   11%	   (5/44)	   chose	  continued	  observation.	  	  For	  case	  2,	  fewer	  opted	  for	  surgical	  resection	  (12/44;	  27%)	  as	  shown	  in	  Figure	  1C.	  
Treatment	  preference	  according	  to	  tumour	  location	  and	  size	  
Questions	   on	   treatment	   preference	   according	   to	   tumour	   size	   and	   location	   were	   not	  consistently	  completed	  by	  all	  neurosurgeons.	  	  For	  superficial	  meningiomas	  surgery	  was	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  the	   treatment	   of	   preference	   for	   convexity	   (33/40;	   83%),	   parasagittal	   (27/39;	   69%),	  parafalcine	   (26/40;	   65%)	   and	   lateral	   sphenoid	   wing	   (30/40;	   75%)	   locations.	  	  Stereotactic	   radiosurgery	   was	   preferred	   for	   the	   treatment	   of	   medial	   sphenoid	   wing	  (16/39;	   41%)	   and	   skull	   base	   tumours	   (23/36;	   64%)	   as	   shown	   in	   Figure	   3.	   	   At	   initial	  clinical	   presentation	   of	   an	   incidental	   meningioma,	   80%	   (24/30)	   of	   neurosurgeons	  reported	   that	   they	   would	   perform	   surgery	   or	   SRS	   if	   the	   tumour	   was	   ≥2.5	   cm	   in	  diameter.	  	  A	  meningioma	  with	  a	  diameter	  of	  ≤1.5	  cm	  would	  receive	  surgery	  or	  SRS	  from	  only	  16%	  (3/19).	  	  At	  follow-­‐up,	  for	  a	  tumour	  with	  a	  diameter	  of	  1.5	  –	  2.5cm,	  surgery	  or	  SRS	  was	  considered	  appropriate	  management	  by	  76%	  (19/25)	  and	  24%	  (5/21)	  tumour	  respectively.	  
Discussion	  
This	  national	  neurosurgical	  survey	  has	  highlighted	  wide	  variation	  in	  the	  current	  clinical	  management	   of	   incidental	   meningioma	   in	   the	   UK.	   	   Several	   trends	   were	   observed,	  namely	  that	  most	  surgeons	  provide	  5-­‐10	  year	  follow-­‐up,	  favour	  surgical	  treatment	  over	  radiosurgery	  and	   that	  at	   the	   initial	  presentation	  of	   incidental	  meningioma	  a	  period	  of	  MRI	  surveillance	  is	  usually	  instituted.	  
	  
Factors	  considered	  in	  patient	  management	  	  
One	  objective	  of	  the	  survey	  was	  to	  identify	  those	  factors	  that	  are	  taken	  into	  account	  by	  neurosurgeons	  when	  developing	  a	  management	  plan.	   	  The	  published	   literature	  on	  the	  natural	   history	   of	   incidental	   meningioma	   comprises	   mainly	   retrospective	   studies.	   	   A	  meta-­‐analysis	  of	  22	  retrospective	  studies	  (n=675)	  revealed	  that	  the	  risk	  for	  developing	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  symptoms	  is	  higher	  for	  a	  meningioma	  between	  2-­‐2.5cm	  in	  initial	  diameter,	  but	  ~50%	  of	  cases	  remain	  static,	  and	  the	  other	  50%	  grow	  at	  an	  annual	  linear	  growth	  rate	  of	  3-­‐75%	  5.	  	  Other	   studies	   suggest	   that	   meningiomas	   may	   reach	   a	   stable	   plateau	   6.	   	   Whilst	   most	  neurosurgeons	   considered	   patient	   factors	   and	   tumour	   location,	   MRI	   features	   were	  considered	   less	   frequently;	   65%	   of	   neurosurgeons	   did	   not	   consider	   absence	   of	  calcification	  as	  an	  influential	  factor,	  and	  peritumoral	  T2	  signal	   intensity	  was	  not	  taken	  into	  account	  by	  23%.	  	  This	  is	  in	  contrast	  with	  the	  combined	  published	  literature	  of	  over	  550	  patients	  that	  shows	  that	  absence	  of	  calcification	  and	  peritumoral	  T2	  signal	  change	  are	  the	  main	  MRI	  features	  associated	  with	  more	  rapid	  meningioma	  growth	  7	  8	  9	  10	  11	  12	  13.	  
Follow-­‐up	  strategies	  
Many	  of	   these	   tumours	  are	   likely	   to	  be	  discussed	  at	   the	  neuro-­‐oncology	  or	   skull	  base	  multi-­‐disciplinary	   team	   (MDT)	   meetings.	   	   The	   follow-­‐up	   of	   brain	   tumours,	   including	  meningiomas,	  consists	  of	  interval	  MRI	  to	  monitor	  tumour	  growth.	  	  Although	  the	  role	  of	  the	  MDT	  in	  managing	   incidental	  meningioma	  was	  not	  specifically	  asked	   in	   the	  survey,	  recommendations	   from	   the	  MDT	  will	   consider	   patient	   age,	   tumour	   location	   and	  MRI	  characteristics.	   	   This	   survey	   highlighted	   that	   early	   follow-­‐up	   MRI	   was	   relatively	  consistent	  between	  neurosurgeons	  as	  approximately	  80%	  chose	  the	  first	  follow-­‐up	  MRI	  scan	  to	  be	  at	  6	  months	  and	  90%	  selected	  subsequent	  MRI	  scans	  to	  be	  12	  monthly.	  	  Some	  neurosurgeons	  highlighted	  that	   the	   frequency	  of	   follow-­‐up	  was	  also	  dependent	  on	  the	  patient	  age	  and	  size	  of	  meningiomas,	  such	  that	  older	  patients	  with	  small	  meningiomas	  could	  undergo	  less	  frequent	  MRI	  scans.	  	  	  Seven	  neurosurgeons	  responded	  that	  an	  initial	  3-­‐month	  MRI	  was	  performed,	  principally	  to	  address	  the	  possibility	  of	  metastatic	  cancer.	  	  For	   a	   meningioma	   with	   a	   typical	   MRI	   appearance,	   however,	   this	   is	   probably	  unnecessary,	   since	   studies	   have	   shown	   that	   the	   initial	   growth	   period	   of	   incidental	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  meningiomas	   is	   low	   14.	   	   Indeed,	   less	   frequent	   use	   of	   MRI	   at	   an	   early	   stage	  may	   also	  reduce	  patient	  anxiety	  as	  well	  as	  being	  more	  cost-­‐effective	  for	  the	  health	  service.	   	  The	  overall	  follow-­‐up	  period	  showed	  the	  most	  discrepancy	  between	  the	  responders.	  	  Stable	  MRI	  scans	  for	  5	  years	  led	  to	  discharge	  by	  42%	  of	  neurosurgeons	  and	  a	  10-­‐year	  follow-­‐up	   was	   preferred	   by	   33%.	   	   A	   recent	   study	   demonstrated	   that	   75%	   of	   incidental	  meningiomas	   will	   show	   growth	   at	   15	   years	   4.	   	   In	   this	   survey,	   three-­‐quarters	   of	  neurosurgeons	   discharge	   stable	   patients	   after	   10	   years,	   which	   may	   miss	   late	  meningioma	   growth.	   	   This	   is	   particularly	   important	   since	   incidental	  meningiomas	   do	  not	   always	   follow	   a	   linear	   growth	   pattern	   and	   unexpected,	   exponential	   growth	   can	  occur	   12.	   	  These	   findings	   should	  be	   taken	   into	  account	  especially	   for	  younger	  patients	  who	  have	  a	  longer	  life	  expectancy.	  
Case	  Scenarios	  
The	   two	   case	   scenarios	   in	   the	   survey	   were	   selected	   to	   create	   a	   standard	  model	   that	  would	  allow	  the	  measurement	  of	  variation	  in	  treatments	  offered	  to	  the	  same	  patient	  by	  different	  neurosurgeons.	   	  Whilst	  most	  neurosurgeons	  elected	  to	  monitor	  both	  cases	  at	  presentation,	   approximately	   10%	   of	   responders	   opted	   for	   surgical	   resection	   in	   the	  younger	   patient,	   even	   though	   the	   tumour	   was	   located	   over	   the	   motor	   strip	   and	   the	  patient	   was	   a	   practising	   dentist.	   	   The	   major	   discrepancy	   occurred	   in	   the	   follow-­‐up	  management	  for	  both	  cases,	  who	  remained	  asymptomatic	  and	  showed	  a	  relatively	  small	  growth	   of	   the	   tumour	   over	   4	   years.	   	   For	   the	   older	   patient,	   approximately	   25%	   chose	  observation	  and	  another	  25%	  preferred	  surgery,	  whereas	  for	  the	  younger	  patient	  48%	  of	   surgeons	   now	   elected	   to	   operate.	   	   SRS	   was	   chosen	   for	   both	   cases	   by	   14%	   of	  neurosurgeons.	   	   The	   variation	   in	   responses	   is	   likely	   to	   reflect	   different	   clinical	  experiences,	  and	  even	  for	  small	  meningiomas	  any	  treatment	  offered	  carries	  some	  risk	  of	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  morbidity	   and	   mortality.	   	   Indeed	   both	   surgery	   and	   SRS	   are	   associated	   with	   higher	  mortality	   in	   older	   patients	   and	   multiple	   studies	   have	   concluded	   that	   conservative	  management	  is	  more	  suitable	  in	  this	  age	  group	  15-­‐18.	  	  Similarly,	  in	  older	  patients	  surgery	  should	  be	  reserved	  for	  large	  symptomatic	  meningiomas.	  
Tumour	  location	  and	  size	  
SRS	   was	   the	   preferred	   treatment	   modality	   for	   medial	   sphenoid	   wing	   and	   skull-­‐base	  tumours,	   which	   reflects	   the	   minimally	   invasive	   nature	   of	   radiosurgery	   compared	   to	  open	   surgery.	   	  However,	   the	   benefits	   of	   SRS	   for	   small	   asymptomatic	  meningioma	   are	  debated,	  since	   it	   is	  used	  for	  smaller	  tumours	  that	  may	  have	   low	  growth	  potential,	  and	  published	   studies	   often	   have	   short	   follow-­‐up	   19.	   	   Although	   the	   natural	   history	   of	  incidental	  meningioma	   is	   that	   50-­‐75%	  will	   grow	  over	   time,	   a	  meningioma	  <2cm	  may	  not	  cause	  symptoms	  5	  and	  treatment	  by	  SRS	  would	  expose	  the	  patient	  to	  unnecessary	  radiation	  and	  potential	  risk	  of	  necrosis.	  	  A	  study	  of	  gamma	  knife	  radiosurgery	  for	  small	  asymptomatic	  meningiomas	  showed	  good	  control	  rates	  but	  a	  4.8%	  adverse	  event	  rate,	  that	   included	   transient	  hemiparesis	   20.	   	   For	  patients	  with	   a	  benign,	   incidental	   tumour	  the	  benefits	  of	   treatment	  should	  always	  outweigh	  the	  risks,	  and	  overtreatment	  should	  be	  avoided.	  
Conclusions	  
Although	  the	  response	  rate	  of	  this	  survey	  study	  was	  only	  12.5%,	  this	  is	  similar	  to	  other	  published	   neurosurgical	   survey	   21.	   	   Since	   responses	   were	   received	   from	   74%	   of	  neurosurgical	   centres,	   the	   findings	   of	   this	   study	   can	   be	   reasonably	   extrapolated	   in	  assessing	  current	  UK	  management	  of	  incidental	  meningiomas.	  	  The	  variation	  in	  follow-­‐up	  and	  the	  case	  scenario	  management	  highlights	  the	  need	  to	  consider	  the	  development	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  of	   guidelines	   that	   can	   facilitate	   clinical	   decision-­‐making.	   	   Treatment	   of	   incidental	  meningiomas	   should	   be	   defined	   on	   an	   individual	   basis	   as	   multiple	   factors	   are	  considered,	   however	   general	   recommendations	   can	   still	   be	   beneficial.	   	   Ultimately	   for	  the	   patient,	   the	   question	   they	   want	   answering	   is	   “will	   my	   incidental	   meningioma	  become	   symptomatic	   and	   will	   I	   need	   treatment	   within	   my	   lifetime?”	   	   To	   provide	   a	  personalised	   estimate	   of	   the	   need	   for	   treatment	   would	   require	   modelling	   of	   growth	  patterns	  in	  relation	  to	  patients,	  clinical	  and	  radiological	  variables.	  	  A	  large,	  multi-­‐centre	  study	  would	  be	  need	  to	  collect	  data	  to	  develop	  a	  ‘risk	  calculator’	  similar	  to	  that	  used	  for	  unruptured	  aneurysms.	  	  The	  health	  economic	  implications	  of	  repeated	  MRI	  and	  clinical	  follow-­‐up	   for	   patients	   with	   asymptomatic	   incidental	   meningiomas	   remains	   unknown	  and	  prospective	  studies	  are	  required	  to	  develop	  algorithms	  that	  minimise	  unnecessary	  treatment	  and	  optimise	  quality	  of	  life.	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Figure	  1	  
Coronal	   contrast	   enhanced	  MRI	   shows	   a	   left	   posterior	   frontal	   convexity	  meningioma	  over	  the	  motor	  cortex	  at	  (A)	  presentation	  with	  a	  2cm	  diameter	  and	  (B)	  four	  years	  later	  with	  a	  2.5cm	  diameter.	  	  The	  clinical	  features	  were	  of	  an	  incidental	  finding	  after	  MRI	  for	  dizziness	   that	   remained	   asymptomatic	   at	   follow-­‐up.	   	   The	   management	   options	   of	  observation,	  surgery	  or	  SRS	  were	  offered	  at	  presentation	  and	  follow-­‐up.	  	  (C)	  In	  scenario	  1,	   the	   patient	   was	   a	   35	   year	   old	   dentist	   and	   at	   initial	   presentation	   neurosurgeons	  selected	   observation	   (39/44),	   surgery	   (3/44)	   or	   were	   uncertain	   (2/44),	   whilst	   at	  follow-­‐up	   there	   was	   a	   preference	   for	   surgery	   (21/44),	   compared	   to	   continued	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  observation	  (5/44),	  SRS	  (6/44)	  or	  uncertainty	  (12/44).	  	  In	  scenario	  2	  the	  patient	  was	  a	  70	   year	   old	   retiree	   and	   at	   initial	   presentation	   observation	   (42/44)	  was	   chosen	  while	  some	  were	  uncertain	  (2/44).	   	  At	  follow-­‐up,	  observation	  (11/44),	  surgery	  (12/44),	  SRS	  (6/44)	  were	  selected	  while	  a	  large	  number	  of	  responders	  were	  uncertain	  (15/44)..	  	  	  




Figure	  2	  	  
Response	  of	  44	  neurosurgeons	  to	  the	  question	  (A)	  “at	  the	  initial	  clinical	  encounter	  what	  clinical	   factors	  would	   influence	   follow-­‐up	   of	   an	   incidental	  meningioma?”	   	   Absence	   of	  calcification	   was	   the	   least	   considered	   tumour	   characteristic	   (36%),	   while	   patient	  preference	  (96%)	  and	  tumour	  location	  (96%)	  were	  the	  most	  considered.	  	  Responses	  to	  the	  question	  (B)	  “what	  frequency	  of	  MRI	  follow-­‐up	  would	  you	  undertake	  at	   initial	  and	  subsequent	  clinical	  encounters	   for	  an	   incidental	  meningioma?”	   	  At	   first	   follow-­‐up	  MRI	  was	  considered	  at	  3	  months	  (7/44),	  6	  months	  (34/44)	  and	  12	  months	  (3/44).	  	  Second	  follow-­‐up	  MRI	  was	  performed	  6	  monthly	  (3/44),	  12	  monthly	  (40/44)	  and	  18	  monthly	  (1/44).	  	  Overall	  follow-­‐up	  was	  5	  years	  (14/33),	  10	  years	  (11/33)	  and	  >10	  years	  (8/33).	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Treatment	  modality	  preference	  according	  to	  anatomical	  location.	  




















Components	  of	  the	  survey	  used	  to	  assess	  clinical	  management.	  
Clinical	  and	  MRI	  factors	   MRI	  follow-­‐up	  schedule	  
• Patient	  preference	   • First	  follow-­‐up	  MRI	  
• Patient	  age	   • Second	  follow-­‐up	  MRI	  
• Co-­‐morbidities	   • Length	  of	  follow-­‐up	  
• Tumour	  location	   • Likelihood	  of	  discharge	  
• Tumour	  size	   	  
• Calcification	   	  
• Peritumoural	  T2	  signal	  change	   	  
	  
